Perspective Therapeutics Announces Plans to Advance Clinical Pipeline, Expand Manufacturing Capacity, and Present Updated Data at 2026 Medical Conferences
I'm PortAI, I can summarize articles.
Perspective Therapeutics Inc. has announced its strategic priorities for the next 12-18 months, focusing on advancing its clinical pipeline and expanding manufacturing capabilities. The company aims to enhance patient recruitment for its lead program, VMT-α-NET, and plans to submit clinical data for regulatory engagement and present updates at medical conferences in 2026. Clinical updates for VMT01 and PSV359 are expected in mid to late 2026, with potential new additions to the pipeline based on imaging data. Manufacturing capacity is also set to increase at existing and newly acquired sites.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments